Specify a stock or a cryptocurrency in the search bar to get a summary
Mainz Biomed BV
MYNZMainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany. Address: Robert Koch Strasse 50, Mainz, Germany, 55129
Analytics
WallStreet Target Price
2 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures MYNZ
Dividend Analytics MYNZ
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History MYNZ
Stock Valuation MYNZ
Financials MYNZ
Results | 2019 | Dynamics |